William C. Bertrand, Jr. Sells 3,770 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock

Adaptimmune Therapeutics plc (NASDAQ:ADAP) COO William C. Bertrand, Jr. sold 3,770 shares of the business’s stock in a transaction dated Tuesday, January 11th. The shares were sold at an average price of $3.56, for a total value of $13,421.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

ADAP stock opened at $3.30 on Friday. Adaptimmune Therapeutics plc has a twelve month low of $3.16 and a twelve month high of $7.34. The stock has a 50-day simple moving average of $3.98 and a two-hundred day simple moving average of $4.45.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Thursday, November 4th. The biotechnology company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.04). Adaptimmune Therapeutics had a negative return on equity of 53.31% and a negative net margin of 2,499.92%. The business had revenue of $1.20 million for the quarter, compared to analysts’ expectations of $1.20 million. During the same period in the previous year, the firm posted ($0.23) EPS. Sell-side analysts expect that Adaptimmune Therapeutics plc will post -0.69 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of ADAP. Marshall Wace LLP purchased a new position in shares of Adaptimmune Therapeutics during the third quarter worth about $8,033,000. Baillie Gifford & Co. grew its holdings in shares of Adaptimmune Therapeutics by 9.6% during the third quarter. Baillie Gifford & Co. now owns 12,824,980 shares of the biotechnology company’s stock worth $66,306,000 after purchasing an additional 1,128,061 shares in the last quarter. PFM Health Sciences LP grew its holdings in shares of Adaptimmune Therapeutics by 45.0% during the second quarter. PFM Health Sciences LP now owns 3,627,900 shares of the biotechnology company’s stock worth $15,455,000 after purchasing an additional 1,126,597 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Adaptimmune Therapeutics by 70.3% during the third quarter. Millennium Management LLC now owns 1,584,849 shares of the biotechnology company’s stock worth $8,194,000 after purchasing an additional 654,434 shares in the last quarter. Finally, Rock Springs Capital Management LP grew its holdings in shares of Adaptimmune Therapeutics by 41.7% during the third quarter. Rock Springs Capital Management LP now owns 2,189,788 shares of the biotechnology company’s stock worth $11,321,000 after purchasing an additional 644,788 shares in the last quarter. 71.38% of the stock is owned by institutional investors.

A number of equities research analysts recently issued reports on ADAP shares. Zacks Investment Research cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 10th. SVB Leerink reaffirmed a “hold” rating and set a $7.00 target price on shares of Adaptimmune Therapeutics in a report on Tuesday, November 9th. Finally, Wells Fargo & Company lifted their target price on Adaptimmune Therapeutics from $6.00 to $7.00 and gave the company an “equal weight” rating in a report on Wednesday, September 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $7.75.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Featured Article: Understanding Specialty Certificates of Deposit

Insider Buying and Selling by Quarter for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.